Use of Alprazolam to Facilitate Mare-Foal Bonding in an Aggressive Postparturient Mare

D.M. Wong, C.J. Alcott, J.L. Davis, K.L. Hepworth, L. Wulf, and J.H. Coetzee

Key words: Behavior; Horse; Maternal; Milk; Neonate; Nursing; Xanax.

A healthy 11-year old, 577 kg maiden Quarter Horse mare was examined at the Lloyd Veterinary Medical Center with a 4-day old colt because the mare would bite or kick the foal when the foal attempted to suckle. The owner bottle fed the foal small amounts of mare’s milk over the first 4 days of life, but the foal became progressively weaker over time and was recumbent and nonresponsive at presentation. Furthermore, although gestational length and parturition were reportedly normal, the mare had apparently not been producing adequate amounts of milk since the foal was born.

Upon presentation (Day 1), the foal weighed 36.8 kg and was severely dehydrated, undernourished, unresponsive, hypothermic (32.2°C; reference range RR, 37.2–38.6°C), bradycardic (40 beats/min; RR, 96–108 beats/min), hypoglycemic (28 mg/dL; RR, 101–226 mg/dL), hyperlactatemic (4.2 mmol/L; RR, <2.5 mmol/L), and had a low serum immunoglobulin G (IgG: 400–800 mg/dL; RR, >800 mg/dL). A CBC revealed leucopenia (3.41 × 10^3/μL; RR, 5.1–10.1 × 10^3/μL) characterized by neutropenia (2.15 × 10^3/μL; RR, 3.21–8.58 × 10^3/μL) and relevant serum biochemistry derangements included hypoproteinemia (3.5 g/dL; RR, 5.3–7.9 g/dL), hypoalbuminemia (1.9 g/dL; RR, 2.8–3.7 g/dL), and hyperbilirubinemia (4.61 mg/dL; RR, 0.5–3.9 mg/dL).

The foal was treated for failure of transfer of passive immunity and polymicrobial sepsis confirmed via blood culture yielding *E. coli* and *Citrobacter sp*. Treatment included administration of 2 L of equine plasma, which increased the serum IgG to >800 mg/dL, fluid resuscitation and treatment, antimicrobial treatment consisting of ceftiofur (Naxel®) (5 mg/kg IV q12h) and gentamicin® (10 mg/kg IV q24h) for 10 days followed by sulfamethoxazole-trimethoprim® (30 mg/kg PO q12h) for 7 days, nasoesophageal tube feedings and supportive and nursing care. The mare was treated with domperidone® (1.1 mg/kg PO q24h) to increase milk production. The foal was able to ambulate by Day 4 and by Day 6, was bright and alert and attempted to suckle from the mare frequently. However, the mare consistently demonstrated aggressive behavior toward the foal; therefore the mare’s head was tied in a stationary position and periodic sedation (detomidine, Dormosedan,® 0.011 mg/kg IM q6h) was administered while the hindlimbs were hobbled to allow the foal to suckle under strict supervision. Although the foal was able to suckle voluntarily, the mare continued to display violent behavior and attempted to bite and kick the foal, but was constrained by the applied restraints.

In an attempt to facilitate mare-foal bonding and provide a means for the foal to suckle unsupervised without maternal sedation or restraint, the mare was administered alprazolam® (0.035 mg/kg PO q8h) on Day 7. On Day 8, 24 hours after the initial dose of alprazolam, the mare had a quieter demeanor and demonstrated less aggression toward the foal. The next day (Day 9) the mare was not aggressive toward the foal and allowed the foal to suckle regularly. Over the next 2 days, the mare was untied, the hobbles were removed and the foal was allowed to suckle without incident. On Day 11, the mare’s physical examination was within acceptable parameters, but the mare appeared mildly sedate; therefore the frequency of alprazolam administration was decreased to twice daily (0.035 mg/kg PO q12h). On Day 14, the foal weighed 44 kg and was suckling regularly without threat from the mare. The mare and foal were subsequently discharged with instructions to administer alprazolam (0.035 mg/kg PO q12h for 3 days, then 0.018 mg/kg PO q12h for 5 days). One week after discharge the owner reported that the mare demonstrated no aggression toward the foal when suckling, and 6 months after presentation the mare and foal were reportedly healthy.
Serum alprazolam concentrations from blood samples collected from the mare were subsequently measured at various time points. Specifically, after owner permission was obtained on Day 7 of hospitalization, 12 mL of blood was collected from the mare, just before the first dose of alprazolam administration (Time 0) and at Times 5, 10, 15, 30, 45, and 60 minutes as well as at 2, 4, 6, 8, 12, 24, 36, and 48 hours after the first alprazolam dose and placed in clot tubes; serum was then harvested and frozen at −80°C until further analysis. Alprazolam and its active metabolite, α-hydroxyalprazolam, concentrations in extracted serum samples were measured via liquid chromatography–ion trap mass spectrometry in positive ion mode. Four daughter ions of the parent pseudomolecular ions at a mass-to-charge ratio of 310.2 and 326.2, respectively, were used for quantification. Hydroxyalprazolam-D5 was used as an internal standard. Separation was achieved on a core-shell C18 column and guard column with a mobile phase consisting of water and acetonitrile each containing 0.1% formic acid. Retention times were 5.2 minutes for alprazolam and 4.8 minutes for α-hydroxyalprazolam. Using this method, standard curves were linear from 0.2 to 50 ng/mL for both compounds, with a coefficient of determination of >0.99 and a coefficient of variation of 2.25% for alprazolam and 2.41% for α-hydroxyalprazolam. After oral administration, alprazolam was quantifiable in plasma by 10 minutes, and α-hydroxyalprazolam by 30 minutes (Fig 1). The maximum concentrations for alprazolam (16.35 ng/mL) and α-hydroxyalprazolam (1.39 ng/mL) were reached at 4 and 6 hours, respectively. Multiple dose administration every 8 hours led to apparent accumulation of drug at the 24, 36, and 48 hour time points (Fig 1).

Normal mare–foal behavior and bonding has been previously described in detail. Difficulties with mare–foal bonding are relatively rare, and with the exception of a severely physically compromised foal, most problems that occur result from inadequate or abnormal maternal behavior. Some aspects of postparturient behavior can appear to be antagonistic or aggressive toward the foal, but the mare against the foal is the most violent and serious abnormal behavior and can be life-threatening (ie, mare tramples or pushes the foal into an obstacle when trying to intervene between the foal and the perceived threat). Finally, savage attack behavior of the mare against the foal is the most violent and serious abnormal behavior and behavior in humans or other animals and in the process the foal is injured (ie, mare tramples or pushes the foal into an obstacle when trying to intervene between the foal and the perceived threat). Maternal behavior in the mare in this report can be described as a combination of ambivalence and nursing avoidance. In the case described here, the nursing avoidance behavior was aggressive enough toward the foal that the foal could not be left unattended with the dam. When common methods of correcting nursing avoidance behavior (ie, supervised nursing with physical restraint of the mare, repeated sedation) were unsuccessful, alprazolam was administered and facilitated the development of appropriate mare–foal behavior over a 2–3 day time period in this case.

Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive medications and is prescribed to treat anxiety and panic disorders in people as well as dogs and cats. The exact mechanism of action is unknown, but similar to other benzodiazepines, alprazolam readily crosses the blood brain barrier and interacts with inhibitory neurotransmitter receptors that are directly activated by gamma-aminobutyric acid receptors (GABA_A) within the central nervous system (CNS). The net result is general slowing of brain activity producing dose-related CNS depression that can vary from mild cognitive impairment (ie, sedation) to hypnosis. In people, alprazolam has a fast onset of action and is readily absorbed after oral administration with plasma concentrations and clinical benefits achieved within the first 1–2 hours of administration. The dosage for alprazolam administration in people ranges from 0.25 to 0.5 mg, PO, q8h for anxiety disorders and up to 10 mg daily for panic disorders. A single 1 mg dose of alprazolam in people resulted in a maximum serum
In summary, administration of alprazolam at a dose of 0.035 mg/kg, PO, q8–12 h was an affordable (<$0.50/dose) method to facilitate healthy mare-foal bonding and behavior in an aggressive mare and ultimately allowed the foal to nurse from the mare while reducing the risk of maternally induced injury to the foal. Of note, however, administration of alprazolam to horses is not approved by the Food and Drug Administration and would be classified as extralabel use.

Footnotes

a Snap Foal IgG Test Kit, IDEXX Laboratories, Westbrook, ME
b Pfizer Animal Health, New York, NY
c Gentacin, MWI, Boise, ID
d Sulfamethoxazole and Trimethoprim, Amneal Pharmaceuticals, Glasgow, KY
e Equidone, Dechra Veterinary Products, Overland Park, KS
f Alprazolam, Sandzor Inc., Princeton, NJ

Kinetics C18 column 100 × 2.1 mm, Phenomenex, Torrance, CA

Acknowledgment

Conflict of Interest Declaration: The authors disclose no conflict of interest.

Off-label Antimicrobial Declaration: The authors declare no off-label use of antimicrobials.

References

1. Grogan EH, McDonnell SM. Mare and foal bonding and problems. Clin Tech Equine Pract 2005;2:228–237.
2. Barber JA, Crowell-Davis SL. Maternal behavior of Belgian (Equus caballus) mares. Appl Anim Behav Sci 1994;41:161–189.
3. Houp KA, Feldman J. Animal behavior case of the month. Aggression toward a neonatal foal by its dam. J Am Vet Med Assoc 1993;203:1279–1280.
4. Houp KA, Olm D. Equine behavior. Eq Pract 1984;6:38–40.
5. Houp KA. Foal rejection and other behavioral problems in the postpartum period. Comp Cont Educ Pract 1984;6:144–148.
6. Verster JC, Volkers ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: A review of the literature. CNS Drug Rev 2004;10:45–76.
7. Crowell-Davis SL, Seibert LM, Sung W, et al. Use of clomipramine, alprazolam, and behavior modification for treatment of storm phobia in dogs. J Am Vet Med Assoc 2003;222:744–748.
8. Seibert LM. Animal behavior case of the month. Urine spraying and inappropriate urination for the past 10 years. J Am Vet Med Assoc 2004;224:1594–1596.
9. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 1993;24:453–471.
10. Package Insert, Alprazolam Tablets. Princeton, NJ: Sandzor Inc; 2012.
11. Wismer TA. Accidental ingestion of alprazolam in 415 dogs. Vet Hum Toxicol 2002;44:22–23.
12. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39–49.